ANDA 91031, held by Hikma Pharmaceuticals. Cefotetan Disodium.
As of Nov 21, 2026, ANDA 91031 (Cefotetan), held by Hikma Pharmaceuticals, was first approved by FDA on Oct 26, 2011, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefotetan and other antibacterial drugs, cefotetan should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 26, 2011 | Original application | Approved | None posted |
| CefotetanEQ 1GM BASE/VIAL · injectable;injection | Cefotetan Disodium | Discontinued |
| CefotetanEQ 2GM BASE/VIAL · injectable;injection | Cefotetan Disodium | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters